search
Back to results

A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome (UNCNT)

Primary Purpose

Menopausal Syndrome

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
MELSMON
UNCNT
Sponsored by
Unimed Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Menopausal Syndrome

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Woman ≥ 40 years old
  • Corresponding to one of the following criteria : Postmenopausal woman

    1. spontaneous amenorrhea for 12 month
    2. Blood serum of FSH concentration exceeds 40mlU/mL, spontaneous amenorrhea for 6month
    3. passed for at least 6 weeks of bilateral ovariectomy
    4. History of bilateral hysterectomy pasted at least 6week and blood serum of FSH more than 40mLU/ml
  • Confirmed using a hot flashes recorded daily diary at visit 2: More 3-4 (times/ per day) moderate or severe flush at least a day or occurrence of more than 20 times a week to check flush
  • Kupperman Index Score ≥ 15 point
  • Serum Estradiol ≤ 30pg/mL
  • Able to communicate to conduct the clinical trial according to the protocol
  • Informed consent by oneself

Exclusion Criteria:

  • Allergic to drugs or any ingredient
  • Psychological menopausal disorder
  • History of carcinoma such as liver cancer etc
  • In the investigator's judgment, which will be unable to participate in this study

    • uncontrolled hypertensive(170/110mmHg more), severe disease (eg., of the cardiovascular, liver, kidney) or diabetic mellitus
  • History of hysterectomy or bilateral ovariectomy within 6 weeks
  • Patients whose blood serum AST/ALT, bilirubin and creatinine are more two times the normal maximum rate.
  • Receiving hormone therapy such as estrogen, progestin or hormone of this class within a month
  • Patients are participated in other clinical trials, and then receiving investigational product within 3 months.
  • Usage of prohibit combination dug
  • history of alcohol and drug abuse
  • Washout requirement for hormone therapy such as estrogen or products involved like estrogen/progestin component ( If who has washout period of following criteria, the subject can participate in this study)

    1. hormonal vaginal formulation (ring, cream, gels, etc) ≥ 1 weeks
    2. estrogen single agent or estrogen/progestin-containing subcutaneous formulation ≥ 4 weeks
    3. Oral estrogen or progestin therapy ≥ 8 weeks
    4. Progestin intrauterine therapy ≥ 8 weeks
    5. single injection of estrogen and progestin formulation transplant ≥3 month
    6. injection of progestin or estrogen pellet method ≥ 6 month
  • In woman ≥40 age, known or suspicion of breast cancer at Breast angiographic and normal pregnancy breast test within 9 month; history of breast cancer; Family history of breast cancer in one generation
  • In Thickness of uterine intima ≥5mm as determined by TUVS, known or suspicion of endometrial hyperplasia or endometrial cancer by performing the endometrial biopsy
  • known or suspicion of Cervical cancer in pap test ( pap smear)
  • otoscleorsis
  • Taking rifampicin induced liver microsome enzyme ( eg., Barbiturates, Hydantion, carbamazepine, mepeu donkey mate, John diphenyl butadiene)
  • Jaundice, Dubin-Johnson syndrome or Rotor syndrome
  • Vaginal bleeding for unknown reason
  • Sickle cell anemia
  • Severe metabolic disorder (eg., porphyria..)
  • Thrombotic phlebitis, thrombosis, embolism patients, or those patients with a history
  • Cerebral, coronary altery disease
  • Thyroid disease, infectious disease
  • Experience of using placenta drug
  • Other circumstances that make the investigator expect an incomplete study participation of the patient

Sites / Locations

  • Inha Univ.Hospital,
  • Korea University Medical center Anam Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

UNCNT

MELSMON

Arm Description

6 times/ 12 days

6 times/ 12 days

Outcomes

Primary Outcome Measures

Kupperman index score
Mean difference of single clinical symptom in Kupperman index from baseline to 12days

Secondary Outcome Measures

E2
Change in blood serum of estradiol from baseline to 12days
FSH (Folic Stimulating Hormone)
Change in blood serum of Follicle-Stimulating Hormone from baseline to 12days.
Hot flushes
Change in frequency and mean differences of hot flushes from baseline to 12days.

Full Information

First Posted
August 21, 2013
Last Updated
May 7, 2014
Sponsor
Unimed Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01931748
Brief Title
A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome
Acronym
UNCNT
Official Title
Study of Non-inferiority UNCNT Versus MELSMON in Female With Menopausal Syndrome: Randomized Confirmatory Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unimed Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Purpose of this study is to evaluate in a randomized, double-blind, Parallel, Non-inferiority, Multicenter, the efficacy and safety of UNCNT in comparison to the active comparator of MELSMON in female having menopausal syndrome. Patients will be allocated randomly to receive either UNCNT or MELSMON. Through the injection of UNCNT to female having menopausal disorder, efficacy in the improvement of the menopausal symptoms by Kupperman index is to be evaluated and compared with MELSMON.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Menopausal Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
104 (Actual)

8. Arms, Groups, and Interventions

Arm Title
UNCNT
Arm Type
Experimental
Arm Description
6 times/ 12 days
Arm Title
MELSMON
Arm Type
Active Comparator
Arm Description
6 times/ 12 days
Intervention Type
Drug
Intervention Name(s)
MELSMON
Other Intervention Name(s)
6 times/ 12 days
Intervention Type
Drug
Intervention Name(s)
UNCNT
Other Intervention Name(s)
6 times/ 12 days
Primary Outcome Measure Information:
Title
Kupperman index score
Description
Mean difference of single clinical symptom in Kupperman index from baseline to 12days
Time Frame
baseline and 12days
Secondary Outcome Measure Information:
Title
E2
Description
Change in blood serum of estradiol from baseline to 12days
Time Frame
baseline and 12days
Title
FSH (Folic Stimulating Hormone)
Description
Change in blood serum of Follicle-Stimulating Hormone from baseline to 12days.
Time Frame
baseline and 12days
Title
Hot flushes
Description
Change in frequency and mean differences of hot flushes from baseline to 12days.
Time Frame
baseline and 12days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Woman ≥ 40 years old Corresponding to one of the following criteria : Postmenopausal woman spontaneous amenorrhea for 12 month Blood serum of FSH concentration exceeds 40mlU/mL, spontaneous amenorrhea for 6month passed for at least 6 weeks of bilateral ovariectomy History of bilateral hysterectomy pasted at least 6week and blood serum of FSH more than 40mLU/ml Confirmed using a hot flashes recorded daily diary at visit 2: More 3-4 (times/ per day) moderate or severe flush at least a day or occurrence of more than 20 times a week to check flush Kupperman Index Score ≥ 15 point Serum Estradiol ≤ 30pg/mL Able to communicate to conduct the clinical trial according to the protocol Informed consent by oneself Exclusion Criteria: Allergic to drugs or any ingredient Psychological menopausal disorder History of carcinoma such as liver cancer etc In the investigator's judgment, which will be unable to participate in this study uncontrolled hypertensive(170/110mmHg more), severe disease (eg., of the cardiovascular, liver, kidney) or diabetic mellitus History of hysterectomy or bilateral ovariectomy within 6 weeks Patients whose blood serum AST/ALT, bilirubin and creatinine are more two times the normal maximum rate. Receiving hormone therapy such as estrogen, progestin or hormone of this class within a month Patients are participated in other clinical trials, and then receiving investigational product within 3 months. Usage of prohibit combination dug history of alcohol and drug abuse Washout requirement for hormone therapy such as estrogen or products involved like estrogen/progestin component ( If who has washout period of following criteria, the subject can participate in this study) hormonal vaginal formulation (ring, cream, gels, etc) ≥ 1 weeks estrogen single agent or estrogen/progestin-containing subcutaneous formulation ≥ 4 weeks Oral estrogen or progestin therapy ≥ 8 weeks Progestin intrauterine therapy ≥ 8 weeks single injection of estrogen and progestin formulation transplant ≥3 month injection of progestin or estrogen pellet method ≥ 6 month In woman ≥40 age, known or suspicion of breast cancer at Breast angiographic and normal pregnancy breast test within 9 month; history of breast cancer; Family history of breast cancer in one generation In Thickness of uterine intima ≥5mm as determined by TUVS, known or suspicion of endometrial hyperplasia or endometrial cancer by performing the endometrial biopsy known or suspicion of Cervical cancer in pap test ( pap smear) otoscleorsis Taking rifampicin induced liver microsome enzyme ( eg., Barbiturates, Hydantion, carbamazepine, mepeu donkey mate, John diphenyl butadiene) Jaundice, Dubin-Johnson syndrome or Rotor syndrome Vaginal bleeding for unknown reason Sickle cell anemia Severe metabolic disorder (eg., porphyria..) Thrombotic phlebitis, thrombosis, embolism patients, or those patients with a history Cerebral, coronary altery disease Thyroid disease, infectious disease Experience of using placenta drug Other circumstances that make the investigator expect an incomplete study participation of the patient
Facility Information:
Facility Name
Inha Univ.Hospital,
City
Incheon
Country
Korea, Republic of
Facility Name
Korea University Medical center Anam Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome

We'll reach out to this number within 24 hrs